3 completed, 2 terminated, 1 withdrawn. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow MMV390048: new trials by email Literature Review of MMV390048 trials Research Report on MMV390048
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemoprotective Activity of MMV390048 in PfSPZ Challenge Model MMV390048 - Malaria,Falciparum | Phase 1 | Withdrawn | Medicines for Malaria Venture | 2018-01-01 | 2018-02-05 | |
| MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria MMV390048 - Malaria | Phase 2 | Terminated | Medicines for Malaria Venture | 8 | 2017-10-20 | 2021-12-09 |
| MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B MMV390048 40mg, MMV390048 dose to be determined mg - Malaria | Phase 1 / Phase 2 | Completed | Medicines for Malaria Venture | 15 | 2016-05-01 | 2017-02-08 |
| Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A MMV390048 40 mg, Placebo to match MMV390048 40 mg, MMV390048 80 mg - Malaria | Phase 1 | Completed | Medicines for Malaria Venture | 24 | 2016-05-01 | 2020-06-11 |
| MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants MMV390048 20mg - Malaria, Falciparum | Phase 1 | Terminated | Medicines for Malaria Venture | 6 | 2014-10-01 | 2020-06-09 |
| Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers MMV390048 5mg, MMV390048 20mg, MMV390048 40mg - Malaria | Phase 1 | Completed | Medicines for Malaria Venture | 48 | 2014-05-01 | 2019-07-17 |
Malaria (5) · Malaria, Falciparum (2)
Medicines for Malaria Venture (6)
Australia (3) · Ethiopia (1) · Germany (1) · South Africa (1)
James McCarthy, Prof (2) · Esayas Gudina, MD (1) · James McCarthy, Dr. (1) · Karen Barnes, Prof (1) · Mezgebu Silamsaw, MD (1)
PMID 31932368, PMID 32239164, PMID 27930660, PMID 36509063
2017 (1)